Tobira Therapeutics Inc. (NASDAQ:TBRA) shares reached a new 52-week low on Tuesday . The stock traded as low as $3.76 and last traded at $3.88, with a volume of 695,330 shares trading hands. The stock had previously closed at $4.07.

A number of brokerages have recently commented on TBRA. Zacks Investment Research raised Tobira Therapeutics from a “hold” rating to a “buy” rating and set a $9.50 price objective on the stock in a report on Saturday, April 23rd. HC Wainwright reissued a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Leerink Swann reissued a “buy” rating and set a $18.00 price objective on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Cowen and Company reissued a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Finally, Cantor Fitzgerald lowered Tobira Therapeutics to a “buy” rating and set a $19.00 price objective on the stock. in a report on Monday, July 25th. Five analysts have rated the stock with a buy rating, Tobira Therapeutics has an average rating of “Buy” and a consensus price target of $16.95.

The firm’s 50 day moving average is $10.69 and its 200 day moving average is $8.62. The firm’s market capitalization is $76.92 million.

Tobira Therapeutics (NASDAQ:TBRA) last posted its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. Analysts forecast that Tobira Therapeutics Inc. will post ($2.49) earnings per share for the current year.

In other news, major shareholder A/S Novo sold 66,814 shares of the business’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $13.04, for a total value of $871,254.56. Following the sale, the insider now directly owns 2,073,022 shares in the company, valued at $27,032,206.88. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

A hedge fund recently bought a new stake in Tobira Therapeutics stock. Marshall Wace LLP bought a new stake in Tobira Therapeutics Inc. (NASDAQ:TBRA) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 107,493 shares of the biopharmaceutical company’s stock, valued at approximately $1,080,000. Marshall Wace LLP owned about 0.57% of Tobira Therapeutics as of its most recent filing with the SEC.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.